公开(公告)号：US09012606B2

公开(公告)日：2015-04-21

申请号：US13265775

申请日：2010-04-22

申请人： Hye-Shin Chung ,  Seung Bum Yoo ,  Sang Mee Lee

发明人： Hye-Shin Chung ,  Seung Bum Yoo ,  Sang Mee Lee

IPC分类号： C07K1/00 ,  C07K14/81

CPC分类号： C07K14/8125 ,  C07K2319/31

摘要： The present invention relates to a fusion protein or peptide, the in vivo half-life of which is increased by maintaining in vivo sustained release, and to a method for increasing in vivo half-life using same. A fusion protein or peptide according to the present invention has excellent in vivo stability by binding a physiologically active protein or physiologically active peptide to an alpha-1 antitrypsin or alpha-1 antitrypsin mutant with one or more amino acids mutated to maintain the in vivo sustained release and to significantly increase the half-life thereof in blood (T1/2) compared to an inherent physiologically active protein or physiologically active peptide. Thus, a fusion protein or peptide according to the present invention can be useful in developing a sustained-release preparation of a protein or peptide drug.

摘要翻译： 本发明涉及通过维持体内持续释放而增加其体内半衰期的融合蛋白或肽，以及使用其增加体内半衰期的方法。 根据本发明的融合蛋白或肽通过将生理活性蛋白或生理活性肽与一个或多个突变的氨基酸结合至α-1抗胰蛋白酶或α-1抗胰蛋白酶突变体而具有优异的体内稳定性，以维持体内持续 与固有的生理活性蛋白质或生理活性肽相比，释放并显着增加血液中的半衰期（T1 / 2）。 因此，根据本发明的融合蛋白或肽可用于开发蛋白质或肽药物的缓释制剂。

公开(公告)号：US20120094356A1

公开(公告)日：2012-04-19

申请号：US13265775

申请日：2010-04-22

申请人： Hye-Shin Chung ,  Seung Bum Yoo ,  Sang Mee Lee

发明人： Hye-Shin Chung ,  Seung Bum Yoo ,  Sang Mee Lee

IPC分类号： C07K19/00 ,  C07K1/00 ,  C12N9/96

CPC分类号： C07K14/8125 ,  C07K2319/31

摘要： The present invention relates to a fusion protein or peptide, the in vivo half-life of which is increased by maintaining in vivo sustained release, and to a method for increasing in vivo half-life using same. A fusion protein or peptide according to the present invention has excellent in vivo stability by binding a physiologically active protein or physiologically active peptide to an alpha-1 antitrypsin or alpha-1 antitrypsin mutant with one or more amino acids mutated to maintain the in vivo sustained release and to significantly increase the half-life thereof in blood (T1/2) compared to an inherent physiologically active protein or physiologically active peptide. Thus, a fusion protein or peptide according to the present invention can be useful in developing a sustained-release preparation of a protein or peptide drug.

摘要翻译： 本发明涉及通过维持体内持续释放而增加其体内半衰期的融合蛋白或肽，以及使用其增加体内半衰期的方法。 根据本发明的融合蛋白或肽通过将生理活性蛋白或生理活性肽与一个或多个突变的氨基酸结合至α-1抗胰蛋白酶或α-1抗胰蛋白酶突变体而具有优异的体内稳定性，以维持体内持续 与固有的生理活性蛋白质或生理活性肽相比，释放并显着增加血液中的半衰期（T1 / 2）。 因此，根据本发明的融合蛋白或肽可用于开发蛋白质或肽药物的缓释制剂。

公开(公告)号：US20090197347A1

公开(公告)日：2009-08-06

申请号：US11571335

申请日：2005-06-28

申请人： Mi Jin Sohn ,  Seung Bum Yoo ,  Yeon Chul Kim ,  Jae Hoon Oh ,  Eunkyung Kim ,  Seung Ho Choo

发明人： Mi Jin Sohn ,  Seung Bum Yoo ,  Yeon Chul Kim ,  Jae Hoon Oh ,  Eunkyung Kim ,  Seung Ho Choo

IPC分类号： G01N33/569 ,  G01N33/566

CPC分类号： G01N33/56905 ,  G01N33/543 ,  G01N2333/445 ,  Y02A50/58

摘要： Disclosed are an immunoassay of Plasmodium falciparum for determining the presence/absence of a specific and/or antibody thereof via label in conjugates bound to the specific antigen and/or antibody present in a sample, comprising immobilizing the specific antigen and antibody of Plasmodium falciparum on a solid phase, adding a sample obtained from a subject of interest to the solid phase so as to induce specific antibody-antigen reaction, adding a conjugate of the antigen and a label and a conjugate of the antibody and a label, separately prepared, so as to induce binding of at least one of the conjugates; and an assay device comprising the above-mentioned solid phase and conjugates.The present invention can effect specific detection of antigens and/or antibodies in patients with manifested malaria-symptoms as well as malaria carriers and can also be efficiently employed in samples at the early stage of malaria infection that is difficult to detect via conventional arts. Further, due to the capacity to utilize sera and blood plasma rather than whole blood, the present invention is well suited to large-scale examination such as blood screening.

摘要翻译： 公开了恶性疟原虫的免疫测定法，用于通过与样品中存在的特异性抗原和/或抗体结合的缀合物中的标记物来确定其特异性和/或抗体的存在/不存在，包括将恶性疟原虫的特异性抗原和抗体固定在 固相，将从感兴趣的受试者获得的样品加入到固相中，以诱导特异性抗体 - 抗原反应，加入分别制备的抗原和抗体的标记物和缀合物和标记的缀合物， 以诱导至少一种缀合物的结合; 以及包含上述固相和缀合物的测定装置。 本发明可以在具有表现的疟疾症状的患者以及疟疾携带者中实现抗原和/或抗体的特异性检测，并且还可以有效地用于通过常规技术难以检测的疟疾感染早期的样品中。 此外，由于能够利用血清和血浆而不是全血，本发明非常适合于大规模检查，如血液筛查。